Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours (Q37177604)

18 August 2017

1 reference

title

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours (English)

1 reference

18 August 2017

1 reference

1

Pasi A Jänne

1 reference

18 August 2017

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

60 Suppl 2

1 reference

18 August 2017

page(s)

S3-9

1 reference

Erlotinib in previously treated non-small-cell lung cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Molecular on/off switch.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Differences in lung cancer risk between men and women: examination of the evidence

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

EGFR inhibitors: what have we learned from the treatment of lung cancer?

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

Genome sequencing in microfabricated high-density picolitre reactors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(08)70099-0

7 January 2021

10.1016/S0169-5002(08)70099-0

Identifiers

DOI

1 reference

18 August 2017

1 reference